床突脑膜瘤的立体定向放射外科治疗:多中心研究
中位随访约51个月,肿瘤进展率为7%,视力下降发生率为8%;较高的边缘处方剂量与更好的肿瘤控制相关,视路受照最大剂量≥10 Gy及SRS前视力缺损增加视力恶化风险。
要点
- SRS对床突脑膜瘤可实现持久控制,多数患者视力得以保留
- 较高的边缘处方剂量与更好的肿瘤控制独立相关
- 视路最大受照剂量≥10 Gy及SRS前视力缺损提示视力下降风险升高
核心结论
- SRS可使多数床突脑膜瘤患者获得持久肿瘤控制并保留视力。
- 较高的放射外科处方剂量与更好的肿瘤控制相关。
- 视路受照剂量≥10 Gy及SRS前视力受损增加视力恶化风险。
研究设计与样本
- 国际放射外科研究基金会12家机构参与的多中心汇总研究。
主要发现
- 中位治疗体积8.02 cm3,87%的肿瘤紧邻视路。
- 中位肿瘤处方剂量12 Gy,前视路中位最大剂量8.5 Gy。
- 中位影像随访51.1个月,7%患者出现肿瘤进展。
- 中位视力随访48个月,8%患者视力功能下降。
- 4例患者出现SRS后新发三叉神经(第V颅神经)病变。
关键数值与推荐
- 较高边缘SRS剂量为更好肿瘤控制的独立预测因素(HR = 0.700,p = 0.007)。
- SRS前放疗为更好肿瘤控制的独立预测因素(HR = 0.004,p < 0.001)。
- SRS前视力缺损独立预测SRS后视力下降风险更高(HR = 2.938,p = 0.048)。
- 视路最大辐射剂量≥10 Gy独立预测SRS后视力下降风险更高(HR = 11.297,p = 0.02)。
临床怎么用
- 对紧邻视路的床突脑膜瘤,SRS可作为保留视力的治疗选择。
- 计划时关注视路最大受照剂量,≥10 Gy者视力下降风险明显升高。
- SRS前已存在视力缺损者应加强治疗后视力监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Resection of clinoid meningiomas can be associated with significant morbidity. Experience with stereotactic radiosurgery (SRS) for clinoid meningiomas remains limited. We studied the safety and effectiveness of SRS for clinoid meningiomas. METHODS: From twelve institutions participating in the International Radiosurgery Research Foundation, we pooled patients treated with SRS for radiologically suspected or histologically confirmed WHO grade I clinoid meningiomas. RESULTS: Two hundred seven patients (median age: 56 years) underwent SRS for clinoid meningiomas. Median treatment volume was 8.02 cm3, and 87% of tumors were immediately adjacent to the optic apparatus. The median tumor prescription dose was 12 Gy, and the median maximal dose to the anterior optic apparatus was 8.5 Gy. During a median post-SRS imaging follow-up of 51.1 months, 7% of patients experienced tumor progression. Greater margin SRS dose (HR = 0.700, p = 0.007) and pre-SRS radiotherapy (HR = 0.004, p < 0.001) were independent predictors of better tumor control. During median visual follow-up of 48 months, visual function declined in 8% of patients. Pre-SRS visual deficit (HR = 2.938, p = 0.048) and maximal radiation dose to the optic apparatus of ≥ 10 Gy (HR = 11.297, p = 0.02) independently predicted greater risk of post-SRS visual decline. Four patients experienced new post-SRS cranial nerve V neuropathy. CONCLUSIONS: SRS allows durable control of clinoid meningiomas and visual preservation in the majority of patients. Greater radiosurgical prescription dose is associated with better tumor control. Radiation dose to the optic apparatus of ≥ 10 Gy and visual impairment before the SRS increase risk of visual deterioration.
引用
- Bunevicius A, Pikis S, Anand RK, et al. Stereotactic radiosurgery for clinoid meningiomas: a multi-institutional study. Acta Neurochir (Wien). 2021. PMID: 34427769. doi:10.1007/s00701-021-04972-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。